Researchers at Georgetown Lombardi Comprehensive Cancer Centre in the US have developed a new biomarker test, TGx-DDI, to accurately identify and predict chemical compounds that could cause DNA damage leading to cancer.

TGx-DDI biomarker panel is based on actively transcribed or expressed genes, which reflect certain pathways responding to different stress types and provide information on cell response to injury such as DNA damage.

The new test is designed to address the concerns with current expensive and time-consuming laboratory tests that are reported to yield more false-positive findings for agents that could cause DNA damage.

A consortium of academic, government and industry investigators by the Health and Environment Science Institute has tested the new biomarker panel with various chemicals and drugs.

“Compared to older tests, our approach allows for very accurate and high-throughput screening of chemical compounds that cause DNA damage and, potentially, cancer in humans.”

In addition to chemicals that were known to cause DNA damage, the consortium used genotoxicity-negative, non-cancer-causing chemicals, along with those known not to cause cancer but were genotoxicity-positive.

The assay delivered positive results for all DNA-damaging agents, negative for all genotoxicity-negative chemicals and nine negatives for a total of ten genotoxicity-positive chemicals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Georgetown Lombardi Comprehensive Cancer Centre member Albert Fornace said that the lack of an accurate, rapid and high-throughput test that assesses genotoxicity has been a major bottleneck in the development of new drugs.

“Compared to older tests, our approach allows for very accurate and high-throughput screening of chemical compounds that cause DNA damage and, potentially, cancer in humans.”